Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...

Sarfaraz K. Niazi, PhD, dives into the role that biosimilar associations and organizations play in promoting biosimilars as ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the ...

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...